Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.

Ann Oncol · 2019 · PMC6927316 · PMID 31868905

Europe PMC DOI

hedged sentences

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

a strong trendP = 0.15not close (p > 0.1)

In CMS3, we observed a strong trend toward longer survival in the cetuximab arm in RAS wt (HR 0.57; P = 0.15).

also in 5,725 other papers

showed a trendno p-value reported

In CMS3, OS showed a trend in favor of the cetuximab arm, while OS was comparable in CMS1 and CMS2, independent of targeted therapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.